AN2 Therapeutics ANTX
NASDAQ ANTX
$4.46 +0.13 (+3.00%)
At close: Nov 11, 2026 · 4:00 PM EST

AN2 Therapeutics (ANTX) Restructuring Costs (2024)

Updated

AN2 Therapeutics (ANTX) recorded Restructuring Costs of -$9,000 in Q4 2024.

Analysis

AN2 Therapeutics (ANTX) Restructuring Costs (2024) Analysis & Trends

For FY2024, AN2 Therapeutics reported Restructuring Costs of $2.23 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 AN2 Therapeutics 164.30 Mn -121.79 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -9,000.00
Sep 30, 2024 2.24 Mn
API Access

AN2 Therapeutics Restructuring Costs API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=restructuring-costs&ticker=ANTX&period=max&api_key=YOUR_API_KEY